Atorvastatin treatment increases plasma bilirubin but not HMOX1 expression in stable angina patients

References

• Troughton JA, Woodside JV, Young IS, Arveiler D, Amouyel P, Ferriéres J, Ducimetiére P, Patterson CC, Kee F, Yarnell JW, Evans A, PRIME Study Group. Bilirubin and coronary heart disease risk in the Prospective Epidemiological Study of Myocardial Infarction (PRIME). Eur J Cardiovasc Prev Rehabil 2007;14:79–84.
   PubMed Web of Science ®Google Scholar
• Djoussé L, Levy D, Cupples LA, Evans JC, D’Agostino RB, Ellison RC. Total serum bilirubin and risk of cardiovascular disease in the Framingham offspring study. Am J Cardiol 2001;87:1196–200.
   PubMed Web of Science ®Google Scholar
• Novotný L, Vítek L. Inverse relationship between serum bilirubin and atherosclerosis in men: a meta-analysis of published studies. Exp Biol Med (Maywood) 2003;228:568–71.
   PubMed Web of Science ®Google Scholar
• Vitek L, Novotný L, Sperl M, Holaj R, Spácil J. The inverse association of elevated serum bilirubin levels with subclinical carotid atherosclerosis. Cerebrovasc Dis 2006;21:408–14.
   PubMed Web of Science ®Google Scholar
• Erdogan D, Gullu H, Yildirim E, Tok D, Kirbas I, Ciftci O, Baycan ST, Muderrisoglu H. Low serum bilirubin levels are independently and inversely related to impaired flow- mediated vasodilation and increased carotid intima-media thickness in both men and women. Atherosclerosis 2006;184:431–7.
   PubMed Web of Science ®Google Scholar
• de Sauvage Nolting PR, Kusters DM, Hutten BA, Kastelein JJ. ExPRESS study group. Serum bilirubin levels in familial hypercholesterolemia: a new risk marker for cardiovascular disease? J Lipid Res 2011;52:1755–9.
   PubMed Web of Science ®Google Scholar
• Lin JP, Vitek L, Schwertner HA. Serum bilirubin and genes controlling bilirubin concentrations as biomarkers for cardiovascular disease. Clin Chem 2010;56:1535–43.
   PubMed Web of Science ®Google Scholar
• Wanq CY, Chau LY. Heme oxygenase 1 in cardiovascular diseases: molecular mechanisms and clinical perspectives. Chang Gung Med J 2010;33:13–24.
   PubMedGoogle Scholar
• Chen JC, Huang KC, Lin WW. HMG-CoA reductase inhibitors upregulate heme oxygenase-1 expression in murine RAW264.7 macrophages via ERK, p38 MAPK and protein kinase G pathways. Cell Signal 2006;18:32–9.
   PubMed Web of Science ®Google Scholar
• Grosser N, Erdmann K, Hemmerle A, Berndt G, Hinkelmann U, Smith G, Schröder H. Rosuvastatin upregulates the antioxidant defense protein heme oxygenase-1. Biochem Biophys Res Commun 2004;325:871–6.
   PubMed Web of Science ®Google Scholar
• Grosser N, Hemmerle A, Berndt G, Erdmann K, Hinkelmann U, Schűrger S, Wijayanti N, Immenschuh S, Schröder H. The antioxidant defense protein heme oxygenase 1 is a novel target for statins in endothelial cells. Free Radic Biol Med 2004;37:2064–71.
   PubMed Web of Science ®Google Scholar
• Hsu M, Muchova L, Morioka I, Wong RJ, Schröder H, Stevenson DK. Tissue-specific effects of statins on the expression of heme oxygenase-1 in vivo. Biochem Biophys Res Commun 2006;343:738–44.
   PubMed Web of Science ®Google Scholar
• Muchova L, Wong RJ, Hsu M, Morioka I, Vitek L, Zelenka J, Schröder H, Stevenson DK. Statin treatment increases formation of carbon monoxide and bilirubin in mice: a novel mechanism of in vivo antioxidant protection. Can J Physiol Pharmacol 2007;85:800–10.
   PubMed Web of Science ®Google Scholar
• Vitek L, Muchova L, Zák A. Statin use and serum bilirubin levels. Atherosclerosis 2011;219:969.
   PubMed Web of Science ®Google Scholar
• Ong KL, Wu BJ, Cheung BM, Barter PJ, Rye KA. Association of lower total bilirubin level with statin usage: The United States National Health and Nutrition Examination Survey 1999–2008. Atherosclerosis 2011;219:728–33.
   Google Scholar
• Ohnaka K, Kono S. Bilirubin, cardiovascular diseases and cancer: epidemiological perspectives. Expert Rev Endocrinol Metab 2010;5:891–904.
   PubMedGoogle Scholar
• Breimer LH, Mikhailidis DP. Is bilirubin a marker of vascular disease and/or cancer and is it a potential therapeutic target? Curr Pharm Des 2011;17:3644–55.
   PubMed Web of Science ®Google Scholar
• Cerne D, Bajalo JL. Cell-free nucleic acids as a non-invasive route for investigating atherosclerosis. Curr Pharm Des 2014;20:5004–9.
   PubMed Web of Science ®Google Scholar
• Stern I, Marc J, Kranjec I, Zorman D, Cerne A, Cerne D. Increased plasma levels of CATS mRNA but not CATB mRNA in patients with coronary atherosclerosis. Clin Biochem 2010;43:1427–30.
   PubMed Web of Science ®Google Scholar
• Cerne D, Stern I, Marc J, Cerne A, Zorman D, Krzisnik-Zorman S, Kranjec I. CTSS activation coexists with CD40 activation in human atheroma: evidence from plasma mRNA analysis. Clin Biochem 2011;44:438–40.
   PubMed Web of Science ®Google Scholar
• Mirjanic-Azaric B, Rizzo M, Sormaz L, Stojanovic D, Uletilovic S, Sodin-Semrl S, Lakota K, Artenjak A, Marc J, Cerne D. Atorvastatin in stable angina patients lowers CCL2 and ICAM1 expression: pleiotropic evidence from plasma mRNA analyses. Clin Biochem 2013;46:1526–31.
   PubMed Web of Science ®Google Scholar
• Fox K, Garcia MA, Ardissino D, Buszman P, Camici PG, Crea F, Daly C, De Backer G, Hjemdahl P, Lopez-Sendon J, Marko J, Morais J, Pepper J, Sechtem U, Simoons M, Thygesen K, Priori SG, Blanc JJ, Budaj A, Camm J, Dean V, Deckers J, Dickstein K, Lekakis J, McGregor K, Metra M, Morais J, Osterspey A, Tamargo J, Zamorano JL. Guidelines on the management of stable angina pectoris: executive summary: The Task Force on the Management of Stable Angina Pectoris of the European Society of Cardiology. Eur Heart J 2006;27:1341–81.
   PubMed Web of Science ®Google Scholar
• Cerne D, Stern I, Kranjec I, Marc J. Optimisation of methods for quantifying plasma mRNA levels from genes responsible for coronary artery plaque development and destabilization. Med Glas (Zenica) 2011;8:90–6.
   PubMedGoogle Scholar
• Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2 (-Delta Delta C (T)) Method. Methods 2001;25:402–8.
   PubMed Web of Science ®Google Scholar
• Jürgens G, Hermann A, Aktuna D, Petek W. Dissociation-enhanced lanthanide fluorescence immunoassay of lipoprotein(a) in serum. Clin Chem 1992;38:853–9.
   PubMed Web of Science ®Google Scholar
• Hammer A, Kager G, Dohr G, Rabl H, Ghassempur I, Jürgens G. Generation, characterization, and histochemical application of monoclonal antibodies selectively recognizing oxidatively modified apoB-containing serum lipoproteins. Arterioscler Thromb Vasc Bio 1995;15:704–13.
   PubMed Web of Science ®Google Scholar
• Pilz J, Meinekea I, Gleitera CH. Measurement of free and bound malondialdehyde in plasma by high-performance liquid chromatography as the 2,4-dinitrophenylhydrazine derivative. J Chromatogr B Biomed Sci Appl 2000;742: 315–25.
   PubMed Web of Science ®Google Scholar
• Esterbauer H, Lang J, Zadravec S, Slater TF. Detection of malonaldehyde by high-performance liquid chromatography. Methods Enzymol 1984;105:319–28.
   PubMed Web of Science ®Google Scholar
• Kawata S, Yamasaki E, Nagase T, Inui Y, Ito N, Matsuda Y, Inada M, Tamura S, Noda S, Imai Y, Matsuzawa Y. Effect of pravastatin on survival in patients with advanced hepatocellular carcinoma. A randomized controlled trial. Br J Cancer 2001;84:886–91.
   PubMed Web of Science ®Google Scholar
• Hu M, Tomlinson B. Effects of statin treatments and polymorphisms in UGT1A1 and SLCO1B1 on serum bilirubin levels in Chinese patients with hypercholesterolaemia. Atherosclerosis 2012;223:427–32.
   PubMed Web of Science ®Google Scholar
• Taleb MH, Almasri IM, Siam NI, Najim AA, Ahmed AI. The effect of atorvastatin on liver function among patients with coronary heart disease in Gaza Strip. Pharmacol Pharmacy 2014;5:781–8.
   Google Scholar
• Ali F, Hamdulay SS, Kinderlerer AR, Boyle JJ, Lidington EA, Yamaguchi T, Soares MP, Haskard DO, Randi AM, Mason JC. Statin-mediated cytoprotection of human vascular endothelial cells: a role for Kruppel-like factor 2-dependent induction of heme oxygenase-1. J Thromb Haemost 2007; 5:2537–46.
   PubMed Web of Science ®Google Scholar
• Lee TS, Chang CC, Zhu Y, Shyy JY. Simvastatin induces heme oxygenase-1: a novel mechanism of vessel protection. Circulation 2004;110:1296–302.
   PubMed Web of Science ®Google Scholar
• Hinkelmann U, Grosser N, Erdmann K, Schröder H, Immenschuh S. Simvastatin-dependent up-regulation of heme oxygenase-1 via mRNA stabilization in human endothelial cells. Eur J Pharm Sci 2010;41:118–24.
   PubMed Web of Science ®Google Scholar
• Dulak J, Loboda A, Jazwa A, Zagorska A, Dörler J, Alber H, Dichtl W, Weidinger F, Frick M, Jozkowicz A. Atorvastatin affects several angiogenic mediators in human endothelial cells. Endothelium 2005;12:233–41.
   PubMed Web of Science ®Google Scholar
• Reichard JF, Motz GT, Puga A. Heme oxygenase-1 induction by NRF2 requires inactivation of the transcriptional repressor BACH1. Nucleic Acids Res 2007;35:7074–86.
   PubMed Web of Science ®Google Scholar
• Florczyk U, Loboda A, Stachurska A, Józkowicz A, Dulak J. Role of Nrf2 transcription factor in cellular response to oxidative stress. Postepy Biochem 2010;56:147–55.
   PubMedGoogle Scholar
• Min KJ, Cho KH, Kwon TK. The effect of oxidized low density lipoprotein (oxLDL)-induced heme oxygenase-1 on LPS-induced inflammation in RAW 264.7 macrophage cells. Cell Signal 2012;24:1215–21.
   PubMed Web of Science ®Google Scholar
• Baranano DE, Rao M, Ferris CD, Snyder SH. Biliverdin reductase: a major physiologic cytoprotectant. Proc Natl Acad Sci USA 2002;99:16093–8.
   PubMed Web of Science ®Google Scholar
• Sedlak TW, Saleh M, Higginson DS, Paul BD, Juluri KR, Snyder SH. Bilirubin and glutathione have complementary antioxidant and cytoprotective roles. Proc Natl Acad Sci USA 2009;106:5171–6.
   PubMed Web of Science ®Google Scholar
• Maghzal GJ, Leck MC, Collinson E, Li C, Stocker R. Limited role for the bilirubin-biliverdin redox amplification cycle in the cellular antioxidant protection by biliverdin reductase. J Biol Chem 2009;284:29251–9.
   PubMed Web of Science ®Google Scholar
• Lin R, Wang Y, Wang Y, Fu W, Zhang D, Zheng H, Yu T, Wang Y, Shen M, Lei R, Wu H, Sun A, Zhang R, Wang X, Xiong M, Huang W, Jin L. Common variants of four bilirubin metabolism genes and their association with serum bilirubin and coronary artery disease in Chinese Han population. Pharmacogenet Genomics 2009;19:310–18.
   PubMed Web of Science ®Google Scholar
• Sticova E, Jirsa M. New insights in bilirubin metabolism and their clinical implications. World J Gastroenterol 2013; 19:6398–407.
   PubMed Web of Science ®Google Scholar
• Zhang W, He YJ, Gan Z, Fan L, Li Q, Wang A, Liu ZQ, Deng S, Huang YF, Xu LY, Zhou HH. OATP1B1 polymorphism is a major determinant of serum bilirubin level but not associated with rifampicin-mediated bilirubin elevation. Clin Exp Pharmacol Physiol 2007;34:1240–4.
   PubMed Web of Science ®Google Scholar
• Wallner M, Marculescu R, Doberer D, Wolzt M, Wagner O, Vitek L, Bulmer AC, Wagner KH. Protection from age- related increase in lipid biomarkers and inflammation contributes to cardiovascular protection in Gilbert's syndrome. Clin Sci (Lond) 2013;125:257–64.
   PubMed Web of Science ®Google Scholar
• Song M, Li A, Gong J, Yang D, Ma L, Zhou X, Yan Y, Xie Y. Effects of combined prednisone + fluvastatin on cholesterol and bilirubin in pediatric patients with minimal change nephropathy. Clin Ther 2013;35:286–93.
   PubMed Web of Science ®Google Scholar
• Li J, Sun YM, Wang LF, Li ZQ, Pan W, Cao HY. Comparison of effects of simvastatin versus atorvastatin on oxidative stress in patients with coronary heart disease. Clin Cardiol 2010;33:222–7.
   PubMed Web of Science ®Google Scholar
• Scheffer PG, Schindhelm RK, van Verschuer VM, Groenemeijer M, Simsek S, Smulders YM, Nanayakkara PW. No effects of atorvastatin and simvastatin on oxidative stress in patients at high risk for cardiovascular disease. Neth J Med 2013;71:359–65.
   PubMed Web of Science ®Google Scholar
• Ky B, Burke A, Tsimikas S, Wolfe ML, Tadesse MG, Szapary PO, Witztum JL, FitzGerald GA, Rader DJ. The influence of pravastatin and atorvastatin on markers of oxidative stress in hypercholesterolemic humans. J Am Coll Cardiol 2008; 51:1653–62.
   PubMed Web of Science ®Google Scholar
• Pittock ST, Norby SM, Grande JP, Croatt AJ, Bren GD, Badley AD, Caplice NM, Griffin MD, Nath KA. MCP-1 is up-regulated in unstressed and stressed HO-1 knockout mice: pathophysiologic correlates. Kidney Int 2005;68: 611–22.
   PubMed Web of Science ®Google Scholar
• Chung J, Shin DY, Zheng M, Joe Y, Pae HO, Ryter SW, Chung HT. Carbon monoxide, a reaction product of heme oxygenase-1, suppresses the expression of C-reactive protein by endoplasmic reticulum stress through modulation of the unfolded protein response. Molec Immunol 2011;48:1793–9.
   PubMed Web of Science ®Google Scholar